Patients with cancer receiving immune checkpoint inhibitors had a twofold higher risk of developing psoriasis than those receiving chemotherapy or targeted therapy, according to the results of a cohort study.
Researchers conducted a nationwide cohort study using data from the Taiwan National Health Insurance database and the Taiwan Cancer Registry.
A total of 135,230 patients with clinical stage III or IV cancer who received antineoplastic medications between January 2019 and June 2021 were included in the study. Patients were classified as ICI users and those who received chemotherapy or targeted therapies were classified as non-ICI users .A total of 295 patients were diagnosed with psoriasis. ICI users experienced a higher incidence of psoriasis than non-ICI users .
Those treated with ICIs had more than a threefold increase in the risk for psoriasis after adjusting for demographic factors and comorbidities and PD-1 ligand-1 inhibitors, as the Taiwan National Health Insurance does not cover cytotoxic T-lymphocyte–associated protein 4 inhibitors.The study was supported by the Ministry of Science and Technology of Taiwan and the Tri-Service General Hospital of Taiwan. One author reported receiving research funding from IQVIA outside the submitted work.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Targeted Therapy Targeted Cancer Therapy Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Biologic Therapy Biologics Chemotherapy Genomics Genomic Medicine Toxicology Toxicity Poisoning Toxins Health Insurance Practice Management Revenue Insurance Protease Inhibitor Atazanavir Darunavir Tipranavir ART - Protease Inhibitor T Cell Adverse Effects Side Effects
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
SGLT2 Inhibitors Associated With Better Survival in PAHThe possible benefit follows similar observations in diabetes, heart failure, and kidney disease, but the potential mechanism remains unknown.
Read more »
Tumor Necrosis Factor Inhibitors Linked to Reduced Recurrent Cardiovascular Events in Radiographic Axial SpondyloarthritisIn patients with axial spondyloarthritis and a history of cardiovascular events, recurrent cardiovascular events were frequent, but exposure to a TNF inhibitor reduced the risk for these events.
Read more »
JAK Inhibitors, Biologics Show Nuanced Differences in Rheumatoid Arthritis Pain OutcomesJAK inhibitors were found to be either marginally more effective or as effective as biologic DMARDs in reducing pain in patients with rheumatoid arthritis in clinical practice.
Read more »
No Excess MACE Risk for JAK Inhibitors in Real-World Atopic Dermatitis AnalysisResults of a retrospective real-world study suggested no greater risk for major CV adverse events in patients treated with upadacitinib and abrocitinib for atopic dermatitis.
Read more »
Review Highlights GI Risks for Biologic Therapies for PsoriasisInterleukin-17 inhibitors showed a higher relative risk for GI events, in a review.
Read more »
Live blog: Israeli strike on army checkpoint kills two Lebanese soldiersTel Aviv's year-long war on Gaza has killed at least 42,126 Palestinians. Separately, Israeli attacks across Lebanon since October 2023 have killed more than 2,169 people and uprooted another 1.2 million.
Read more »